Tectonic Therapeutic Inc.
- Address
- 490 Arsenal Way
Sponsor Overview
Specializations
Cardiovascular and pulmonary vascular disease
Tectonic Therapeutic Inc. focuses on clinical research in pulmonary hypertension linked to heart failure with preserved ejection fraction (HFpEF), with attention to haemodynamic impairment in patients affected by combined postcapillary and precapillary pulmonary hypertension and isolated postcapillary pulmonary hypertension.
- Pulmonary hypertension
- PH-HFpEF
- Combined postcapillary and precapillary pulmonary hypertension
- Isolated postcapillary pulmonary hypertension
The sponsor’s research interest centres on therapies intended to address elevated pulmonary vascular resistance and the clinical burden associated with HFpEF-related pulmonary vascular disease.
Haemodynamic and cardiopulmonary function
Its clinical programme includes evaluation of treatment effects on mean pulmonary vascular resistance and safety in patients with cardiopulmonary disease, reflecting a therapeutic focus on vascular and cardiac interaction in pulmonary hypertension.
- Pulmonary vascular resistance
- Mean PVR
- Cardiopulmonary haemodynamics
- Heart failure-related pulmonary hypertension
Research activity is directed toward clinical settings where elevated filling pressures and pulmonary vascular changes coexist, especially in HFpEF populations.
Heart failure and vascular medicine
The sponsor is engaged in studies at the intersection of heart failure and pulmonary vascular disease, with therapeutic interest in patients whose pulmonary hypertension arises secondary to preserved left ventricular function.
- HFpEF
- Secondary pulmonary hypertension
- Postcapillary pulmonary hypertension
- Pulmonary vascular disease
These studies place emphasis on conditions that are clinically challenging because of overlapping cardiac and pulmonary mechanisms.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Efficacy and Safety Evaluation of TX000045 in Pulmonary Hypertension Secondary to Heart Failure with Preserved Ejection Fraction: A Randomized, Placebo-Controlled Study |  Austria Belgium Bulgaria Germany Latvia Poland Portugal Romania Spain | Not Recruiting |
| Single-Dose, Open-Label Evaluation of TX000045 in Patients with Combined or Isolated Postcapillary Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction |  The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.
This sponsor has worked with 27 sites across their trial portfolio.
Therapeutic Focus
- 1.Cardiovascular Diseases2 trials359 other sponsors
Partnered Research Centres
27 centres- Address
- Konstantin Pomyanov Str 1, 1415 Sofia
- Address
- Langenbeckstrasse 1, Oberstadt, 55131 Mainz
- Address
- Largo Professor Abel Salazar, 4050-011 Porto
- Address
- Ulitsa Dimitir Mollov 1, 1750 Sofia
- Address
- Strada Marinescu Gheorghe 50, 540136 Târgu Mureş
- Address
- Calle Valle De La Ballestera 59, 46015 Valencia
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Tectonic Therapeutic Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.